Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + docetaxel + S-1 as first-line therapy for metastatic gastric cancer
ChiCTR-OIC-17011385Phase 2Recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- May 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib, docetaxel and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: progression-free survival. Started May 2017; status: recruiting.
02
Drugs
Rivoceranibdocetaxeltegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-OIC-17011385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011385.